Perspective Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Perspective Therapeutics CEO'su Thijs Spoor, Feb2023 tarihinde atandı, in görev süresi 1.75 yıldır. in toplam yıllık tazminatı $ 1.46M olup, şirket hissesi ve opsiyonları dahil olmak üzere 34.7% maaş ve 65.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.031% ine doğrudan sahiptir ve bu hisseler € 237.21K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 1.8 yıldır.

Anahtar bilgiler

Thijs Spoor

İcra Kurulu Başkanı

US$1.5m

Toplam tazminat

CEO maaş yüzdesi	34.7%
CEO görev süresi	1.8yrs
CEO sahipliği	0.03%
Yönetim ortalama görev süresi	1.7yrs
Yönetim Kurulu ortalama görev süresi	1.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Thijs Spoor'un ücretlendirmesi Perspective Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$52m
Mar 31 2024	n/a	n/a	-US$50m
Dec 31 2023	US$1m	US$506k	-US$37m

Tazminat ve Piyasa: Thijs 'ın toplam tazminatı ($USD 1.46M ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.42M ).

Tazminat ve Kazançlar: Thijs şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Thijs Spoor (52 yo)

1.8yrs

Görev süresi

US$1,458,996

Tazminat

Mr. Johan M. Spoor, also known as Thijs, is Chief Executive Officer and Director at Perspective Therapeutics, Inc. (formerly known as Isoray, Inc.) since February 05, 2023. He founded AzurRx BioPharma, Inc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Johan Spoor	CEO & Director	1.8yrs	US$1.46m	0.031% € 237.2k
Jonathan Hunt	CFO and Principal Financial & Accounting Officer	5.9yrs	US$1.17m	0.053% € 411.1k
Markus Puhlmann	Chief Medical Officer	1.8yrs	US$900.09k	0.20% € 1.6m
Shane Cobb	Executive Vice President of Operations	1.3yrs	Veri yok	Veri yok
Michael Schultz	Chief Science Officer	no data	Veri yok	2.2% € 17.0m
Annie Cheng	Vice President of Investor Relations	no data	Veri yok	Veri yok
Andrew Bright	Executive Vice President of Brachytherapy	1.6yrs	Veri yok	Veri yok
Amos Hedt	Chief Business Strategy Officer	no data	Veri yok	Veri yok
Frances Johnson	Chief Innovation Officer	no data	Veri yok	2.2% € 17.0m
David Hauser	Senior Vice President of Clinical Operations	no data	Veri yok	Veri yok
Steve Keefe	Senior Vice President of Clinical Development	less than a year	Veri yok	Veri yok

1.7yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: AAJ0 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Johan Spoor	CEO & Director	1.8yrs	US$1.46m	0.031% € 237.2k
Robert Williamson	Independent Director	1.8yrs	US$320.06k	0.063% € 488.6k
Frank Morich	Independent Director	1.8yrs	US$320.06k	Veri yok
Heidi Henson	Independent Director	1.4yrs	US$390.70k	Veri yok
Lori Holmes-Woods	Chairperson of the Board	6.4yrs	US$671.73k	0.24% € 1.9m

1.8yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AAJ0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.8 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Perspective Therapeutics Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

High number of new and inexperienced directors

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Chief Medical Officer recently bought €128k worth of stock

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

Recent updates

Perspective Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy (212Pb)Vmt01 Based on Data Presented At the 21St International Congress of the Society for Melanoma Research

High number of new and inexperienced directors

Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CEO & Director recently bought €109k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings released: US$0.024 loss per share (vs US$0.002 loss in 1Q 2023)

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

New minor risk - Revenue size

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought €128k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought €172k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.029 loss in 3Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Second quarter 2023 earnings released: US$0.04 loss per share (vs US$0.015 loss in 2Q 2022)

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Second quarter 2023 earnings released: US$0.02 loss per share (vs US$0.011 loss in 2Q 2022)

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings released: US$0.029 loss per share (vs US$0.016 loss in 1Q 2022)

Insufficient new directors

Isoray, Inc. to Report Q1, 2023 Results on Nov 10, 2022

Full year 2022 earnings released: US$0.051 loss per share (vs US$0.033 loss in FY 2021)

Isoray, Inc. (NYSEAM:ISR) entered into an Agreement and Plan of Merger to acquire Viewpoint Molecular Targeting, Inc.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş